Baseline demographic and clinical characteristics of 82 patients
| Characteristic . | Patients . |
|---|---|
| Median age, y (range) | 67 (39-86) |
| Sex, no. (%) | |
| Male | 56 (68) |
| Female | 26 (32) |
| ECOG performance status, no. (%) | |
| 0 | 40 (49) |
| 1 | 42 (51) |
| Median time since MDS diagnosis, mo (range) | 8.8 (0-128) |
| Prior therapy for MDS, no. (%) | 30 (37) |
| Transfusion dependence at baseline, no. (%) | |
| Red blood cells | 57 (70) |
| Platelets | 11 (13) |
| MDS classification, no. (%) | |
| FAB classification | |
| RAEB | 40 (49) |
| RAEB-t | 23 (28) |
| CMML | 19 (23) |
| WHO classification | |
| RAEB-1 | 2 (2) |
| RAEB-2 | 40 (49) |
| CMML-1 | 8 (10) |
| CMML-2 | 9 (11) |
| AML-TLD | 18 (22) |
| AML | 5 (6) |
| IPSS score | |
| High | 32 (39) |
| Int-2 | 29 (35) |
| Int-1 | 8 (10) |
| Not applicable* | 13 (16) |
| Characteristic . | Patients . |
|---|---|
| Median age, y (range) | 67 (39-86) |
| Sex, no. (%) | |
| Male | 56 (68) |
| Female | 26 (32) |
| ECOG performance status, no. (%) | |
| 0 | 40 (49) |
| 1 | 42 (51) |
| Median time since MDS diagnosis, mo (range) | 8.8 (0-128) |
| Prior therapy for MDS, no. (%) | 30 (37) |
| Transfusion dependence at baseline, no. (%) | |
| Red blood cells | 57 (70) |
| Platelets | 11 (13) |
| MDS classification, no. (%) | |
| FAB classification | |
| RAEB | 40 (49) |
| RAEB-t | 23 (28) |
| CMML | 19 (23) |
| WHO classification | |
| RAEB-1 | 2 (2) |
| RAEB-2 | 40 (49) |
| CMML-1 | 8 (10) |
| CMML-2 | 9 (11) |
| AML-TLD | 18 (22) |
| AML | 5 (6) |
| IPSS score | |
| High | 32 (39) |
| Int-2 | 29 (35) |
| Int-1 | 8 (10) |
| Not applicable* | 13 (16) |
IPSS was not applicable because of no baseline karyotype (n = 2), secondary MDS (n = 4), or proliferative CMML (n = 7).